SMARCB1 and malignant myoepithelioma: Additional immunohistochemical markers such as GFAP, which may be positive in myoepithelioma/myoepithelial carcinoma, and SMARCB1, which may show mosaic loss specifically in OFMT [1,2], are useful for such differential diagnosis.